Login
Companies $CNTX
$0.18 +$0.01 (5.61%) After hours
Context Therapeutics Inc. logo

Context Therapeutics Inc.

contexttherapeutics.com

What Do They Do?

Develops antibody drugs designed to direct immune cells against solid tumors, including ovarian, pancreatic and bladder cancers.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +21% (Loss)
vs −$9.7M in Q3 FY2025
  • Jul 29, 2026 Nasdaq notified the company of a minimum bid-price deficiency The company had until January 25, 2027, to regain compliance by meeting the $1.00 minimum bid price for 10 consecutive business days.
  • Jun 15, 2026 CTIM-76 trial results included confirmed ovarian-cancer responses 2 of 7 evaluable patients had confirmed partial responses in platinum-resistant ovarian cancer; cytokine release syndrome was Grade 1 in 1 of 9 at active doses.

Pipeline refocus The older report described a progesterone-receptor drug for female cancers alongside an antibody candidate targeting a tumor protein, and said it was exploring options for the former. The latest report describes antibody candidates targeting solid tumors.

Who Do They Compete With?

Competes with Beigene, Third Arc Bio, Xencor, Daiichi Sankyo, BioNTech, TORL, Amgen, RemeGen Biosciences, Outpace Bio, Navrogen, Bicycle Therapeutics, Pfizer, Eli Lilly, Corbus Pharmaceuticals, Bio-Thera, Mabwell, Adcentrx, Aktis Oncology, and Shanghai Henlius Biotech

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support